上海交通大学学报（医学版）

上海交通大学学报（医学版） >

2023 , Vol. 43 >Issue 9: 1107 - 1114

DOI: https://doi.org/10.3969/j.issn.1674-8115.2023.09.005

论著 · 基础研究

ASGR1在肝细胞癌中的意义及机制研究

  • 李倩玉 ,
  • 郭文韵 ,
  • 钱逸斐 ,
  • 李松玲 ,
  • 朱子俊 ,
  • 刘艳丰
展开
  • 1.上海交通大学医学院附属仁济医院临床干细胞研究中心，上海 200127
    2.上海交通大学生物医学工程学院Med-X研究院，上海 200030
    3.上海交通大学医学院附属仁济医院肝外科，上海 200127
李倩玉（1997—），女，硕士生；电子信箱：qianyu_lli@163.com。
刘艳丰，电子信箱：lyf7858188@163.com。

收稿日期: 2023-08-16

  录用日期: 2023-09-18

  网络出版日期: 2023-09-28

基金资助

国家自然科学基金(82073190);上海交通大学医学院“双百人”项目(20221704)

收起

Study on the significance and mechanism of ASGR1 in hepatocellular carcinoma

  • Qianyu LI ,
  • Wenyun GUO ,
  • Yifei QIAN ,
  • Songling LI ,
  • Zijun ZHU ,
  • Yanfeng LIU
Expand
  • 1.Renji-Med X Clinical Stem Cell Research Center, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
    2.School of Biomedical Engineering & Med-X Research Institute, Shanghai Jiao Tong University, Shanghai 200030, China
    3.Department of Liver Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
LIU Yanfeng, E-mail: lyf7858188@163.com.

Received date: 2023-08-16

  Accepted date: 2023-09-18

  Online published: 2023-09-28

Supported by

National Natural Science Foundation of China(82073190);“Two-hundred Talents”Program of Shanghai Jiao Tong University School of Medicine(20221704)

Fold

摘要

目的·探究去唾液酸糖蛋白受体1（asialoglycoprotein receptor 1，ASGR1）在肝细胞癌（hepatocellular carcinoma，HCC）中的意义及潜在机制。方法·通过R语言分析癌症基因组图谱（The Cancer Genome Atlas，TCGA）数据库中ASGR1在肝癌患者中的表达情况并绘制相关生存曲线。利用人类蛋白质图谱（The Human Protein Atlas，HPA）数据库获得人体正常肝组织和肝癌组织的免疫组织化学（immunohistochemistry，IHC）数据来分析ASGR1的蛋白表达情况。利用流体动力学尾静脉注射（hydrodynamic tail vein injection，HTVI）递送方法，在免疫完全的小鼠肝脏中敲除Asgr1探究其在体内的致瘤功能，并通过蛋白免疫印迹法（Western blotting，WB）验证基因敲除效率。利用R语言进行京都基因与基因组百科全书（Kyoto Encyclopedia of Genes and Genomes，KEGG）通路富集分析及相关性分析，利用基因探针富集（Gene Set Enrichment Analysis，GSEA）软件进行GSEA hallmark相关通路分析，利用实时荧光定量PCR（quantitative real-time PCR，qPCR）在小鼠肝癌组织中验证糖酵解关键基因表达水平。结果·ASGR1在肝癌组织中显著低表达，在肝癌患者中ASGR1的低表达与患者较差的总体生存期（overall survival，OS）、无疾病间隔（disease free interval，DFI）、无进展间隔期（progression free interval，PFI）和疾病特异性生存期（disease specific survival，DSS）相关；肿瘤分级程度越高的肝癌患者ASGR1基因表达水平越低。人体正常肝组织ASGR1蛋白的表达显著高于肝癌组织。在免疫完全的肝细胞癌小鼠模型中，小鼠内源性Asgr1敲除可增加肝组织中肿瘤结节的大小和数量。TCGA数据库中ASGR1低表达组肝癌患者富集到多条癌症及代谢相关通路，ASGR1表达与部分糖酵解关键基因表达呈负相关，Asgr1敲除组的小鼠肝癌组织中糖酵解水平高于对照组，提示ASGR1低表达很可能促进肝癌的生长发展，加强代谢重编程促进肿瘤的合成代谢发展。结论·ASGR1在肝癌患者中表达显著降低，与患者的预后呈正相关；小鼠体内敲除Asgr1可促进肝细胞癌的发生发展；ASGR1可以作为肝癌预后不良的潜在生物标志物和潜在治疗新靶点。

关键词： 去唾液酸糖蛋白受体1（ASGR1）; 肝细胞癌; 流体动力学尾静脉注射; 治疗靶点

本文引用格式

李倩玉 , 郭文韵 , 钱逸斐 , 李松玲 , 朱子俊 , 刘艳丰 . ASGR1在肝细胞癌中的意义及机制研究[J]. 上海交通大学学报（医学版）, 2023 , 43(9) : 1107 -1114 . DOI: 10.3969/j.issn.1674-8115.2023.09.005

Abstract

Objective ·To explore the significance and mechanism of asialoglycoprotein receptor 1 (ASGR1) in hepatocellular carcinoma. Methods ·The expression of ASGR1 in patients with liver cancer in The Cancer Genome Atlas (TCGA) database was analyzed by R language and the related survival curves were drawn. The Human Protein Atlas (HPA) database was used to obtain the immunohistochemistry (IHC) data of normal human liver tissue and liver cancer tissue to analyze the protein expression of ASGR1. By using the hydrodynamic tail vein injection (HTVI) delivery method, Asgr1 was knocked out in the liver of fully immune mice to explore its tumorigenic function invivo. Gene knockout efficiency was verified by Western blotting (WB). The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis and correlation analysis were performed by using R language. The GSEA hallmark correlation pathway analysis was performed by using Gene Set Enrichment Analysis (GSEA) software. The expression level of key genes of glycolysis in mouse liver cancer tissue was verified by quantitative real-time PCR (qPCR). Results ·ASGR1 was significantly low-expressed in liver cancer tissue, and the low expression of ASGR1 in liver cancer patients was associated with poorer overall survival (OS), disease-free interval (DFI), progression-free interval (PFI), and disease-specific survival (DSS). The higher the degree of tumor grade, the lower the expression level of ASGR1 in patients with liver cancer. Immunohistochemistry showed that the protein expression of ASGR1 in normal human liver tissue was significantly higher than that in liver cancer tissue. In an immunocompetent mouse model of hepatocellular carcinoma, knockout of endogenous Asgr1 in mice increased the size and number of tumor nodules in liver tissue. In the TCGA database, patients with liver cancer in the ASGR1 low-expression group were enriched in multiple cancer and metabolic pathways. The expression of ASGR1 was negatively correlated with some key genes of glycolysis. The level of glycolysis in liver cancer tissues of mice in the Asgr1 knockout group was higher than that in the control group. It was suggested that the low expression of ASGR1 be likely to promote the growth and development of liver cancer and strengthen metabolic reprogramming to promote the anabolic development of tumors. Conclusion ·The expression of ASGR1 is significantly reduced in patients with liver cancer, which is positively correlated with the prognosis of patients. Knocking out Asgr1 in mice can promote the occurrence and development of hepatocellular carcinoma. ASGR1 can be used as a potential biomarker for poor prognosis of liver cancer and a new target for potential treatment.

Key words： asialoglycoprotein receptor 1 (ASGR1); hepatocellular carcinoma; hydrodynamic tail vein injection; therapeutic target

参考文献

1 BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
2 SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
3 SINGAL A G, LAMPERTICO P, NAHON P. Epidemiology and surveillance for hepatocellular carcinoma: new trends[J]. J Hepatol, 2020, 72(2): 250-261.
4 SINGH M K, DAS B K, CHOUDHARY S, et al. Diabetes and hepatocellular carcinoma: a pathophysiological link and pharmacological management[J]. Biomed Pharmacother, 2018, 106: 991-1002.
5 ASHWELL G, HARFORD J. Carbohydrate-specific receptors of the liver[J]. Annu Rev Biochem, 1982, 51: 531-554.
6 TANOWITZ M, HETTRICK L, REVENKO A, et al. Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes[J]. Nucleic Acids Res, 2017, 45(21): 12388-12400.
7 夏梦蝶, 廖韦, 向琼, 等. 去唾液酸糖蛋白受体1在动脉粥样硬化中的研究进展[J]. 中国动脉硬化杂志, 2022, 30(6): 541-545.
7 XIA M D, LIAO W, XIANG Q, et al. Research progress of asialoglycoprotein receptor 1 in atherosclerosis[J]. Chinese Journal of Arteriosclerosis, 2022, 30(6): 541-545.
8 DE GALARRETA M R, BRESNAHAN E, MOLINA-SáNCHEZ P, et al. β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma[J]. Cancer Discov, 2019, 9(8): 1124-1141.
9 SIEGEL R L, MILLER K D, WAGLE N S, et al. Cancer statistics, 2023[J]. CA A Cancer J Clinicians, 2023, 73(1): 17-48.
10 RAHIB L, SMITH B D, AIZENBERG R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States[J]. Cancer Res, 2014, 74(11): 2913-2921.
11 ZHOU J, SUN H C, WANG Z, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition)[J]. Liver Cancer, 2020, 9(6): 682-720.
12 EL-SERAG H B. Hepatocellular carcinoma[J]. N Engl J Med, 2011, 365(12): 1118-1127.
13 LLOVET J M, KELLEY R K, VILLANUEVA A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 6.
14 Gilbert Ashwell: sweet on science[J]. Nat Med, 2008, 14(6): 608.
15 GREWAL P K. The ashwell-morell receptor[J]. Methods Enzymol, 2010, 479: 223-241.
16 SUGAHARA K, TOGASHI H, TAKAHASHI K, et al. Separate analysis of asialoglycoprotein receptors in the right and left hepatic lobes using Tc-GSA SPECT[J]. Hepatology, 2003, 38(6): 1401-1409.
17 GREWAL P K, UCHIYAMA S, DITTO D, et al. The Ashwell receptor mitigates the lethal coagulopathy of sepsis[J]. Nat Med, 2008, 14(6): 648-655.
18 WANG J Q, LI L L, HU A, et al. Inhibition of ASGR1 decreases lipid levels by promoting cholesterol excretion[J]. Nature, 2022, 608(7922): 413-420.
19 RIGOPOULOU E I, ROGGENBUCK D, SMYK D S, et al. Asialoglycoprotein receptor (ASGPR) as target autoantigen in liver autoimmunity: lost and found[J]. Autoimmun Rev, 2012, 12(2): 260-269.
20 WITZIGMANN D, QUAGLIATA L, SCHENK S H, et al. Variable asialoglycoprotein receptor 1 expression in liver disease: implications for therapeutic intervention[J]. Hepatol Res, 2016, 46(7): 686-696.
21 GU D, JIN H, JIN G, et al. The asialoglycoprotein receptor suppresses the metastasis of hepatocellular carcinoma via LASS2-mediated inhibition of V-ATPase activity[J]. Cancer Lett, 2016, 379(1): 107-116.
22 ZHU X X, SONG G Y, ZHANG S Y, et al. Asialoglycoprotein receptor 1 functions as a tumor suppressor in liver cancer via inhibition of STAT3[J]. Cancer Res, 2022, 82(21): 3987-4000.
23 TONG M, WONG T L, ZHAO H, et al. Loss of tyrosine catabolic enzyme HPD promotes glutamine anaplerosis through mTOR signaling in liver cancer[J]. Cell Rep, 2021, 36(8): 109617.
24 FAUBERT B, SOLMONSON A, DEBERARDINIS R J. Metabolic reprogramming and cancer progression[J]. Science, 2020, 368(6487): eaaw5473.
25 YEH Y C, HO H L, WU Y C, et al. AKT1 internal tandem duplications and point mutations are the genetic hallmarks of sclerosing pneumocytoma[J]. Mod Pathol, 2020, 33(3): 391-403.
26 H?NIGOVA K, NAVRATIL J, PELTANOVA B, et al. Metabolic tricks of cancer cells[J]. Biochim Biophys Acta BBA Rev Cancer, 2022, 1877(3): 188705.
27 CAI J, SUN X H, GUO H, et al. Non-metabolic role of UCK2 links EGFR-AKT pathway activation to metastasis enhancement in hepatocellular carcinoma[J]. Oncogenesis, 2020, 9(12): 103.
28 ICARD P, SIMULA L, WU Z R, et al. Why may citrate sodium significantly increase the effectiveness of transarterial chemoembolization in hepatocellular carcinoma?[J]. Drug Resist Updat, 2021, 59: 100790.
29 BUONTEMPO F, ERSAHIN T, MISSIROLI S, et al. Inhibition of Akt signaling in hepatoma cells induces apoptotic cell death independent of Akt activation status[J]. Invest New Drugs, 2011, 29(6): 1303-1313.
30 TIAN L Y, SMIT D J, JüCKER M. The role of PI3K/AKT/mTOR signaling in hepatocellular carcinoma metabolism[J]. Int J Mol Sci, 2023, 24(3): 2652.
Options
文章导航

/

〈 〉